Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.
Newman
Amy Hauck
AH
National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, Maryland 21224, USA. anewman@intra.nida.nih.gov
Grundt
Peter
P
Nader
Michael A
MA
D000818:Animals; D001682:Biological Availability; D018491:Dopamine Agonists / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D065127:Dopamine D2 Receptor Antagonists; D006801:Humans; D017448:Receptors, Dopamine D2 / Q000819:agonists*; D050637:Receptors, Dopamine D3; D013329:Structure-Activity Relationship; D019966:Substance-Related Disorders / Q000188:drug therapy*
C493593:DRD3 protein, human; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3